61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Orion Oyj (Class B)
Closed
50.56 -0.39
Overview
Share price change
24h
Min
50.3
Max
50.92
Income | 109M 161M |
|---|---|
Sales | 143M 471M |
P/E Sector Avg | 29.83 59.526 |
EPS | 1.14 |
Dividend yield | 3.291 |
Profit margin | 34.118 |
EBITDA | 162M 228M |
Dividend yield Sector Avg | 3.29% 2.33% |
|---|
Market Cap | 571M 5.2B |
|---|---|
Previous open | 50.95 |
Previous close | 50.56 |
Orion Oyj (Class B) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Orion Oyj (Class B) Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Orion Oyj (Class B)
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
